Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation and preparation metheod of vaccine preparation

A tumor peptide vaccine, CT26 technology, applied in the direction of anti-tumor drugs, chemical instruments and methods, peptides, etc., can solve the problem of general anti-tumor immune effect

Active Publication Date: 2020-09-04
WUXI APPTEC SUZHOU
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the current therapeutic tumor vaccines are mostly MHCI-restricted neoantigen fragments that can cause CD8 T cells to respond, and the effect of anti-tumor immunity is mediocre.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation and preparation metheod of vaccine preparation
  • Mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation and preparation metheod of vaccine preparation
  • Mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation and preparation metheod of vaccine preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Whole exome sequencing and mRNA gene expression sequencing.

[0032] The CT26 tumor cell DNA was randomly broken into 150-200bp with an ultrasonic disruptor. After the magnetic beads were purified, the product was repaired and flattened by the end, and an A base was added to the 3 end to form a sticky end. Then, connect with a linker containing a specific barcode sequence. Magnetic bead screening removes incompletely connected products and self-connected products. Use universal primers complementary to the adapter sequence to perform PCR amplification to form a sequencing library. Then use Agilent probes to hybridize in hybridization buffer, use magnetic beads to capture the hybridized target fragments and separate and purify them. PCR amplifies the captured DNA fragments and purifies the PCR products to obtain a sequencing library. Qubit detects library concentration and Agilent 2100Bioanalyzer detects library fragment length. Finally, Illumina was used for...

Embodiment 2

[0033] Example 2: Prediction of tumor neoantigens.

[0034] Analyzing the data obtained by whole exome sequencing, a total of 1259 mutant peptide fragments were found in CT26 cells (Table 1). We used two tools, NetMHC and NetMHCpan, to predict the CD8 T cell epitope of these 1259 mutant peptide sequences. We scored the neoantigen mutation sequence according to the algorithm of the analysis tool, and then selected the top 20 mutant sequences with scores. Synthesize peptide fragments by chemical synthesis.

[0035] Such as figure 2 As shown, the exons of tumor cells were sequenced and analyzed, combined with gene expression analysis, to predict the mutant polypeptides produced by the mutations, and then the software NetMHC and NetMHCpan were used to perform MHC I restricted binding analysis on the mutant polypeptides, and it was predicted that they could be Mutant polypeptide fragments processed and presented by antigen-presenting cells. Then, according to the software score and t...

Embodiment 3

[0038] Example 3: ELISOPT screening of immunogenic mutant antigens

[0039] Mix 20 chemically synthesized mutant polypeptide fragments together with the adjuvant Poly:IC, and immunize BABL / C mice on the right back of the hind limbs. On the 7th day, a booster immunization will be carried out. After 14 days of immunization, take the small Mouse spleen, prepare splenic single cell suspension, and screen out the T cell epitope of the mutant antigen by ELISPOT technology. To produce IFN-γ spots greater than or equal to 10 / 5×10 5 A spleen cell is the positive standard. From the 20 mutant peptide fragments, a total of 7 polypeptide fragments with immunogenic mutant antigen CD8 T cell epitopes (see image 3 And Table 2).

[0040] Table 2 Polypeptide sequence in the present invention

[0041] SEQ ID NO:1P2Ufl1 KYQGLVVKQSV SEQ ID NO: 2P3Ufl1 VKYQGLVVKQSV SEQ ID NO: 3P4Ufl1 KYQGLVVKQSVK SEQ ID NO: 4P7 Rik DYVTGKMAV SEQ ID NO: 5P16 Nap14 SYIETLPKAIK SEQ ID NO: 6P17 Igf2r KYVFINVCHRV ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation. The vaccine preparation comprises an antigen epitope composition and an adjuvant. The antigenepitope composition comprises seven polypeptide fragments of CT26 CD8 T cell epitopes (as shown in SEQ ID NO: 1-7) and four polypeptide fragments of CT26 CD4 T cell epitopes (as shown in SEQ ID NO: 8-11). The vaccine preparation provides a new approach to improve the therapeutic effect of other CT26 tumor vaccines, improves the inhibitory effect of tumor growth, and is suitable for exploration incombination therapy of other types of anti-tumor drugs. The invention also discloses a preparation method of the polypeptide vaccine preparation. The preparation method comprises: tumor neoantigen prediction, screening, identification, polypeptide vaccine preparation development, and in vivo pharmacodynamic test and pharmacokinetic test of the polypeptide vaccine preparation.

Description

Technical field [0001] The present invention belongs to the field of immunotherapy, and particularly relates to a therapeutic tumor vaccine, in particular to a mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation; in addition, the invention also relates to the mouse CT26 colorectal cancer therapeutic tumor polypeptide vaccine preparation The preparation method. Background technique [0002] Tumor has always been one of the greatest threats to human health. Its pathogenesis is complicated and the patient population is huge. It has become the disease with the highest mortality rate in my country. Facing the severe challenges of malignant tumors, many pharmaceutical companies have devoted themselves to the development of tumor treatment drugs. The tumor treatment drug market has shown a rapid expansion in recent years. In the rapidly expanding anti-tumor therapy market, tumor immunotherapy drugs are attracting attention. Among them, immune checkpoint inhib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K39/39A61P35/00C07K7/06C07K7/08C07K14/00
CPCA61K39/001102A61K39/39A61P35/00C07K7/06C07K7/08C07K14/00
Inventor 冀群升韦睿成王晶晶冯旭龙徐亦清王迪闫雪冰谷庆阳石晓翮
Owner WUXI APPTEC SUZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com